Allosteric regulation of Keap1 by 8β-hydroxy-acyclocostunolide for the treatment of acute lung injury  

作　　者：Juan Zhang Min Zhang Qi-Meng Zhu Xin-Rong Xu Yan-Li Feng Sheng Lin Feng Qiu Cheng-Peng Sun 

机构地区：[1]School of Chinese Materia Medic1,Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China [2]Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第9期4174-4178,共5页药学学报（英文版）

基　　金：National Natural Science Foundation of China(No.82274069,82030116,and 82141212);China Postdoctoral Science Foundation(No.2022M720095 and 2023T160434);Young Elite Scientists Sponsorship Programby China Association of Chinese Medicine(No.2022-QNRC2-B09).

摘　　要：To the Editor:Acute lung injury(ALI)is a debilitating lung disease characterized by pulmonary edema,diffuse alveolar damage,and uncontrolled neutrophil infiltration^(1).Severe cases of ALI can potentially lead to the development of acute respiratory distress syndrome(ARDS),which can lead to impaired respiratory function,multiorgan dysfunction,and an extremely high mortality rate^(2-4).ALI may be caused by various factors,including aspiration,severe pneumonia,sepsis,trauma,fatty embolism,pancreatitis,and blood transfusion^(3).Current clinical approaches to treating ALI/ARDS include mechanical ventilation,extracorporeal membrane oxygenation(ECMO),and other supportive therapies^(5,6).Therefore,ALI/ARDS is an urgent problem that needs to be addressed in the field of respiratory critical care and innovative mechanisms and therapies^(6).

关 键 词：Macrophage overactivation KEAP1 8β-Hydroxy-a-cyclocostunolide Nrf2 Acute lung injury 

分 类 号：R575[医药卫生—消化系统]